6533b85ffe1ef96bd12c1cf6

RESEARCH PRODUCT

Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy

Philip Maximilian KnaffPatrick MüllerTanja SchirmeisterStefan HammerschmidtHannah MausChristian KerstenVolker Mailänder

subject

PharmacologySerine proteaseCathepsinProteasesbiologySARS-CoV-2Organic ChemistryVirus Internalizationmedicine.disease_causeBiochemistryVirologyTransmembrane proteinVirusCOVID-19 Drug TreatmentSpike Glycoprotein CoronavirusDrug Discoverybiology.proteinmedicineHumansMolecular MedicineSerine ProteasesReceptorFurinCoronavirus

description

Abstract: Due to its fast international spread and substantial mortality, the coronavirus disease COVID-19 evolved to a global threat. Since there is currently no causative drug against this viral infection available, science is striving for new drugs and other approaches to treat the new disease. Studies have shown that the cell entry of coronaviruses into host cells takes place through the binding of the viral spike (S) protein to cell receptors. Priming of the S protein occurs via hydrolysis by different host proteases. The inhibition of these proteases could impair the processing of the S protein, thereby affecting the interaction with the host-cell receptors and preventing virus cell entry. Hence, inhibition of these proteases could be a promising strategy for treatment against SARSCoV- 2. In this review, we discuss the current state of the art of developing inhibitors against the entry proteases furin, the transmembrane serine protease type-II (TMPRSS2), trypsin, and cathepsin L.

https://doi.org/10.2174/0929867328666210526111318